Quantcast
Last updated on April 18, 2014 at 9:56 EDT

Latest Guanidines Stories

2013-10-21 16:25:57

INCLINE VILLAGE, Nev., Oct. 21, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed (NASDAQ: DEPO) in exchange for a $240.5 million cash payment. PDL will receive all royalty and milestone payments due under the agreements until it has received payments equal to two times the cash payment made to Depomed, after which all...

2013-10-21 16:25:51

Cash to support future product acquisitions NEWARK, Calif., Oct. 21, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has sold its interests in royalty and milestone payments under its license agreements in the Type 2 diabetes therapeutic area to PDL BioPharma, Inc. for $240.5 million. Depomed intends to use the sale proceeds to acquire products that will drive long-term growth and build on the company's commercial expertise in pain and neurology. The...

2013-10-21 08:29:05

SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today the completion of a 12-week Phase 2b study of NewMet(TM), a delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx previously reported that the study met its primary endpoint of statistically significant reduction in fasting plasma glucose at four weeks of treatment with NewMet compared to placebo. The 12-week data confirm the durability of the effect observed...

2013-09-30 23:26:54

Reportbuyer.com just published a new market research report: Diabetes Treatments: World Drug Market 2013-2023. London (PRWEB) September 30, 2013 Report Details How to find trends, opportunities and revenue prospects in treating diabetes Where's the diabetic treatments market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities. Our study lets you...

2013-09-24 23:26:58

Premium quality pre- and post-workout products deliver results at affordable prices. Las Vegas, NV (PRWEB) September 24, 2013 Wellness and supplement manufacturer DrVita announces their new performance-enhancing brand, DrMuscle, will premiere at the 2013 Mr. Olympia Show from October 26-29 in Las Vegas. DrMuscle products are scientifically formulated to maximize effectiveness, made in DrVita’s new, state of the art GMP-certified facility in Las Vegas, Nevada, and all delivered at a...

2013-09-17 23:33:14

Kidney Disease Solution penned by Duncan Capicchiano is a newly updated natural treatment book that teaches people how to lower creatinine levels quickly. A complete Kidney Disease Solution overview on the website Vkoolelite indicates if the book is worth buying. Seattle, WA (PRWEB) September 17, 2013 Kidney Disease Solution book is penned by Duncan Capicchiano – a fully qualified Naturopath and a co-founder of a leading wellness clinic in Melbourne. This man also is a full member of...

2013-09-17 08:31:27

SAN DIEGO, Sept. 17, 2013 /PRNewswire/ -- Elcelyx Therapeutics today announced that clinical advisor, John Buse, M.D., Ph.D., will present clinical data for NewMet(TM), a delayed-release formulation of generic metformin, in an oral presentation at the 49th Annual European Association for the Study of Diabetes (EASD) Meeting in Barcelona, Spain. Dr. Buse, Professor of Medicine and Director, Diabetes Care Center, Chief, Division of Endocrinology, Executive Associate Dean for Clinical Research...

2013-09-09 16:24:22

NEWARK, Calif., Sept. 9, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today it has expanded the geographic scope of its non-exclusive license agreement with a subsidiary of Merck for certain patents directed to metformin extended release technology for use in JANUMET(®) XR (sitagliptin and metformin hydrochloride (HCl) extended-release). The territory covered by the license agreement is now worldwide. Under terms of the agreement originally entered into in July 2009,...

2013-09-04 08:31:37

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that NewMet(TM), the delayed-release formulation of generic metformin for the treatment of patients with Type 2 diabetes, met its primary study endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo. The results from the randomized, 240-patient, multicenter U.S. Phase 2b trial confirm previous studies that showed NewMet reduced...

2013-09-04 08:31:35

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that it has formed NaZura BioHealth, a separate company established to focus on the development of Gut Sensory Modulators (GSM) including lead product Lovidia(TM), a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet(TM), the company's proprietary delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx has funded...